CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity
The prognosis of patients with acute myeloid leukemia (AML) remains dismal, highlighting
the need for novel innovative treatment strategies. The application of chimeric antigen …
the need for novel innovative treatment strategies. The application of chimeric antigen …
[HTML][HTML] Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
M Ruella, DM Barrett, SS Kenderian… - The Journal of …, 2016 - Am Soc Clin Investig
Potent CD19-directed immunotherapies, such as chimeric antigen receptor T cells (CART)
and blinatumomab, have drastically changed the outcome of patients with …
and blinatumomab, have drastically changed the outcome of patients with …
Emerging cellular therapies for cancer
Genetically engineered T cells are powerful new medicines, offering hope for curative
responses in patients with cancer. Chimeric antigen receptor (CAR) T cells were recently …
responses in patients with cancer. Chimeric antigen receptor (CAR) T cells were recently …
[HTML][HTML] Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML
Targeted immunotherapy in acute myeloid leukemia (AML) is challenged by the lack of AML-
specific target antigens and clonal heterogeneity, leading to unwanted on-target off …
specific target antigens and clonal heterogeneity, leading to unwanted on-target off …
[HTML][HTML] Cooperative CAR targeting to selectively eliminate AML and minimize escape
S Haubner, J Mansilla-Soto, S Nataraj, F Kogel… - Cancer cell, 2023 - cell.com
Acute myeloid leukemia (AML) poses a singular challenge for chimeric antigen receptor
(CAR) therapy owing to its phenotypic heterogeneity and similarity to normal hematopoietic …
(CAR) therapy owing to its phenotypic heterogeneity and similarity to normal hematopoietic …
[HTML][HTML] Integrating proteomics and transcriptomics for systematic combinatorial chimeric antigen receptor therapy of AML
Chimeric antigen receptor (CAR) therapy targeting CD19 has yielded remarkable outcomes
in patients with acute lymphoblastic leukemia. To identify potential CAR targets in acute …
in patients with acute lymphoblastic leukemia. To identify potential CAR targets in acute …
[HTML][HTML] A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity
MY Kim, R Jayasinghe, JM Devenport… - Nature …, 2022 - nature.com
Chimeric antigen receptor (CAR) T cell therapy is routinely used to treat patients with
refractory hematologic malignancies. However, a significant proportion of patients …
refractory hematologic malignancies. However, a significant proportion of patients …
[HTML][HTML] CAR T cells redirected to cell surface GRP78 display robust anti-acute myeloid leukemia activity and do not target hematopoietic progenitor cells
Developing CAR T cells for acute myeloid leukemia (AML) has been hampered by a paucity
of targets that are expressed on AML blasts and not on hematopoietic progenitor cells …
of targets that are expressed on AML blasts and not on hematopoietic progenitor cells …
Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia
Chimeric antigen receptor (CAR) T cells have radically improved the treatment of B cell–
derived malignancies by targeting CD19. The success has not yet expanded to treat acute …
derived malignancies by targeting CD19. The success has not yet expanded to treat acute …
Versatile strategy for controlling the specificity and activity of engineered T cells
JSY Ma, JY Kim, SA Kazane, S Choi… - Proceedings of the …, 2016 - National Acad Sciences
The adoptive transfer of autologous T cells engineered to express a chimeric antigen
receptor (CAR) has emerged as a promising cancer therapy. Despite impressive clinical …
receptor (CAR) has emerged as a promising cancer therapy. Despite impressive clinical …